Brean Murray Maintains 'Buy' on Keryx (KERX); Focus Shifts to Less Risky Zerenex
Tweet
Share
E-mail
Get Alerts KERX Hot Sheet
Price: $3.36 --0%
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
6 Buy, 10 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Brean Murray Carret & Co. maintains a 'Buy' on Keryx Biopharmaceuticals (NASDAQ: KERX) price target halved to $5.
Analyst, Jonathan Aschoff, said, "KERX announced top-line data for the Phase 3 X-PECT trial, where perifosine in combo with capecitabine failed to meet the primary endpoint in the treatment of coloretal cancer (CRC). Due to this outcome, KERX is also reevaluating the Phase 3 program of perifosine in relapsed and refractory multiple myeloma patients. Given the unfortunate outcome in CRC, our focus is now on the Phase 3 program for Zerenex...We continue to believe that Zerenex offers a great deal of value to patients and to shareholders with the share price down where it is at present."
Aschoff lowers FY12 loss from (0.44) to (0.47) and FY13 from (0.14) to (0.37)
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.98 yesterday.
Analyst, Jonathan Aschoff, said, "KERX announced top-line data for the Phase 3 X-PECT trial, where perifosine in combo with capecitabine failed to meet the primary endpoint in the treatment of coloretal cancer (CRC). Due to this outcome, KERX is also reevaluating the Phase 3 program of perifosine in relapsed and refractory multiple myeloma patients. Given the unfortunate outcome in CRC, our focus is now on the Phase 3 program for Zerenex...We continue to believe that Zerenex offers a great deal of value to patients and to shareholders with the share price down where it is at present."
Aschoff lowers FY12 loss from (0.44) to (0.47) and FY13 from (0.14) to (0.37)
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
